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Possible Recurrent 
Pandemic (H1N1) 
2009 Infection, 
Israel
To the Editor: We report 2 cas-
es of possible recurrent laboratory-
conﬁ   rmed infection with pandemic 
(H1N1) 2009 virus in Israel. Patient 
1, a 24-year-old man, had Noonan 
syndrome (1,2). He was hospitalized 
on August 10, 2009, because of high-
grade fever and cough. At admission, a 
nasopharyngeal specimen was collect-
ed for pandemic (H1N1) 2009 virus 
real-time reverse transcription–PCR 
(RT-PCR) (ABI 7500; Applied Bio-
systems, Foster City, CA, USA) for 
the pandemic hemagglutinin gene; a 
validated in-house protocol developed 
at Israel Central Virology Laboratory 
was used, as previously described (3). 
Brieﬂ  y, the in-house assay was vali-
dated against the assay for pandemic 
(H1N1) 2009 virus developed by the 
Centers for Disease Control and Pre-
vention (CDC; Atlanta, GA, USA). 
The in-house assay was as sensitive as 
the CDC assay; however, the in-house 
primers and probes were more speciﬁ  c 
for detecting pandemic (H1N1) 2009 
virus with 105% ampliﬁ  cation  efﬁ  -
ciency of viral RNA that was logarith-
mically serially diluted. In addition, of 
100 samples tested side by side with 
the in-house and CDC assays, 75 sam-
ples were positive by both assays, and 
25 were negative by both assays; thus, 
the sensitivity and speciﬁ  city of the in-
house assay were 100%.
The patient was not treated with 
neuraminidase inhibitors and did not 
require supportive treatment; after 
1 day of hospitalization, he was dis-
charged with a diagnosis of upper 
respiratory tract infection. The labo-
ratory subsequently reported the RT-
PCR as positive for pandemic (H1N1) 
2009 virus. On November 22, the man 
was hospitalized again for dyspnea 
and fever. The RT-PCR result from a 
nasopharyngeal sample collected at 
admission was positive. Hemaggluti-
nation-inhibition assay demonstrated 
a high titer (320) of serum antibody 
against pandemic (H1N1) 2009 virus 
in a blood sample taken at admission. 
The patient took oseltamivir for 5 
days, and his condition markedly im-
proved. Result of a repeat RT-PCR at 
discharge was negative.
An identical neuraminidase gene 
sequence was detected during both 
illness episodes (August and Novem-
ber). The specimens were also tested 
with an experimental RT-PCR assay 
for rapid detection of the oseltamivir 
resistance mutation H275Y on the 
pandemic neuraminidase gene (4). 
For specimens collected during both 
episodes, the virus was oseltamivir 
sensitive. 
Patient 2, a 13.5-year-old boy, 
had severe cerebral palsy. On July 
27, 2009, high-grade fever with dys-
pnea developed. He was treated as an 
outpatient for 5 days with oseltamivir 
and clinically improved. However, on 
August 11, he had fever with respira-
tory distress and was hospitalized. RT-
PCR for pandemic (H1N1) 2009 virus 
was positive on August 14.  A second 
course of oseltamivir was administered 
for 10 days with the dosage adjusted 
for age and doubled from that of the 
previous regimen. Further testing with 
the experimental rapid RT-PCR indi-
cated the viral strain had the oseltami-
vir resistance mutation. On September 
14, RT-PCR was negative. 
On December 11, the boy was 
again hospitalized because of respi-
ratory distress and high-grade fever. 
On December 14, RT-PCR was posi-
tive for pandemic (H1N1) 2009 virus, 
and a 5-day regimen of oseltamivir 
was started. Another specimen taken 
the same day was negative. A high se-
rum antibody titer (320) to pandemic 
(H1N1) 2009 virus was measured by 
hemagglutination-inhibition assay on 
December 16; no oseltamivir resis-
tance mutation was found. Additional 
laboratory testing included a complete 
panel for respiratory viruses, which 
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was negative for human metapneu-
movirus; respiratory syncytial virus; 
adenovirus; seasonal inﬂ  uenza  virus 
types A and B; and parainﬂ  uenza virus 
types 1, 2, and 3.
These 2 cases of possible recur-
rent pandemic (H1N1) 2009 infec-
tion demonstrated a wide interval 
between illness episodes. Neither pa-
tient had accompanying immunodeﬁ  -
ciency, and both had antibody titers 
far beyond the accepted seroprotec-
tive threshold for inﬂ  uenza (5), albeit 
ineffective. These titers probably re-
sulted from primary infection rather 
than from subclinical exposure, 
which manifests itself as a lower titer 
by order of magnitude (6,7).
Virus clearance was not labora-
tory conﬁ  rmed for patient 1 after the 
ﬁ  rst episode because no samples were 
taken after hospital discharge. Patient 
2 had both positive and negative RT-
PCRs for pandemic (H1N1) 2009 
virus (Table) from samples collected 
the same day during the second hos-
pitalization, which also may disprove 
reinfection. The positive result could 
be explained by laboratory contami-
nation during the RT-PCR processing 
that indicated a false-positive result. 
However, contamination is unlikely 
because each run of the RT-PCR was 
routinely accompanied by runs of 
negative controls (that contain wa-
ter) to rule out such contamination. 
Nonanalytic factors such as specimen 
misidentiﬁ  cation also are unlikely be-
cause the central virology laboratory, 
which is the national reference center, 
has an ISO-9000 qualiﬁ  cation from 
the Standards Institution of Israel 
(www.sii.org.il/20-en/SII_EN.aspx). 
Furthermore, no other respiratory 
virus was found by laboratory test-
ing at that time. The patient was in-
fected with an oseltamivir-resistant 
pandemic (H1N1) 2009 virus during 
the ﬁ  rst illness episode and with an 
oseltamivir-sensitive virus during the 
second episode and had 2 RT-PCRs 
with negative results between the 
episodes.
The novel pandemic inﬂ  uenza 
virus may be able to reinfect certain 
chronically ill persons. Caregivers 
should be aware of this trait when 
considering the differential diagnosis 
of inﬂ   uenza-like illness in a patient 
with a documented, and even treated, 
pandemic (H1N1) 2009 infection.
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Table. Real-time RT-PCR for pandemic (H1N1) 2009 virus and results of experimental 
assay* for oseltamivir resistance mutation H275Y, Israel, 2009† 
Date 
Patient 1  Patient 2 
RT-PCR 
Oseltamivir 
resistance/sensitivity RT-PCR 
Oseltamivir 
resistance/sensitivity
Aug 10  Positive  Sensitive  – –
Aug 14  – – Positive  Resistant
Aug 19  – – Positive  Resistant
Sep 1  – – Positive  Resistant
Sep 14  – – Negative –
Nov 22  Positive  Sensitive  Negative –
Nov 29  Negative – – –
Dec 14  – – Positive  Sensitive 
Dec 14  – – Negative –
Dec 17  – – Negative –
Dec 21  – – Negative –
*Source: (4).
†RT-PCR, reverse transcription–PCR; –, not tested. 